CAN-BIND Investigator Team

  • 2Articles
  • 16.3KReads1
  • 2019–2020Active
  • 34Collaborators
  • 98Citations2

About

The CAN-BIND Investigator Team has published research focused on major depressive disorder (MDD), specifically examining symptom dimensions related to treatment strategies involving escitalopram and aripiprazole. Their work includes studies on symptom and functional outcomes as well as early prediction of treatment response in patients with MDD. Members of the team are affiliated with the CAN-BIND consortium, with detailed information available at www.canbind.ca/about-can-bind/our-team/.

Publications

JCP
Original Research

Interest-Activity Levels and Need for AD Augmentation in MDD

June 16, 2020

Depressed people who have lost interest and are inactive may not respond well to antidepressants. This study examined whether depressed subjects with low interest and activity who responded poorly...
, , , et al
JCP
Original Research

CAN-BIND-1 Outcomes and Early Response Prediction in MDD

February 5, 2019

Antidepressant medications are often prescribed with little certainty about their potential effectiveness in individual patients. Can early symptom reduction help predict later symptomatic and functional outcomes of antidepressant treatment?...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe